Association of Serum Calprotectin (S100A8/A9) Level With Disease Relapse in Proteinase 3–Antineutrophil Cytoplasmic Antibody–Associated Vasculitis Academic Article uri icon

Overview

MeSH Major

  • Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
  • Immunologic Factors
  • Leukocyte L1 Antigen Complex
  • Rituximab

abstract

  • An increase in serum S100A8/A9 level by month 2 or 6 compared to baseline identifies a subgroup of PR3-ANCA patients treated with RTX who are at higher risk of relapse by 18 months. Since RTX is increasingly used for remission induction in PR3-ANCA-positive patients experiencing a relapse, S100A8/A9 level may assist in identifying those patients requiring more intensive or prolonged treatment.

publication date

  • January 2017

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1002/art.39814

PubMed ID

  • 27428710

Additional Document Info

start page

  • 185

end page

  • 193

volume

  • 69

number

  • 1